Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > A Little Disappointed

<< Previous

Bullboard Posts

Next >>

Post by TheMadMonkon Feb 14, 2023 8:27pm

552 Views

Post# 35286458

A Little Disappointed

The new anticipated start date for the Phase II bunionectomy trial is now calendar Q4 2023. On the plus side this gives me more time to continue to average down since there does not appear to be a catalyst for this stock until the fall. Who knows, maybe it can creep back below 50 cents with this new delay.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023